CN104435262A - Medicine composition for treating infantile viral myocarditis - Google Patents
Medicine composition for treating infantile viral myocarditis Download PDFInfo
- Publication number
- CN104435262A CN104435262A CN201410834156.XA CN201410834156A CN104435262A CN 104435262 A CN104435262 A CN 104435262A CN 201410834156 A CN201410834156 A CN 201410834156A CN 104435262 A CN104435262 A CN 104435262A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine composition
- radix
- herba
- viral myocarditis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 206010047470 viral myocarditis Diseases 0.000 title claims abstract description 17
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title claims description 12
- 241000005787 Cistanche Species 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 241000628997 Flos Species 0.000 claims description 12
- 239000003826 tablet Substances 0.000 claims description 8
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 6
- 241000196324 Embryophyta Species 0.000 claims description 6
- 241001290564 Fimbristylis Species 0.000 claims description 6
- 241000522192 Hylodesmum podocarpum Species 0.000 claims description 6
- 241000123113 Phellinus igniarius Species 0.000 claims description 6
- 241001092459 Rubus Species 0.000 claims description 6
- 244000295490 Salvia japonica Species 0.000 claims description 6
- 235000005794 Salvia japonica Nutrition 0.000 claims description 6
- 241000756523 Tricyrtis Species 0.000 claims description 6
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 6
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims 2
- 241000700605 Viruses Species 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 230000002107 myocardial effect Effects 0.000 abstract description 4
- 210000004165 myocardium Anatomy 0.000 abstract description 4
- 208000009525 Myocarditis Diseases 0.000 abstract description 2
- 240000005748 Achyranthes aspera Species 0.000 abstract 1
- 235000005517 Achyranthes aspera Nutrition 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 208000035240 Disease Resistance Diseases 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 241000123107 Phellinus Species 0.000 abstract 1
- 241001621994 Soroseris gillii Species 0.000 abstract 1
- 230000002155 anti-virotic effect Effects 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 210000002064 heart cell Anatomy 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 229940126673 western medicines Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 5
- 241000723353 Chrysanthemum Species 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 206010006580 Bundle branch block left Diseases 0.000 description 1
- 206010006578 Bundle-Branch Block Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 206010064550 Myocarditis post infection Diseases 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 201000001715 left bundle branch hemiblock Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000007529 rheumatic myocarditis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine composition for treating infantile viral myocarditis. The medicine composition comprises cassia twig, liquorice, orange peel, chaff flower root, glossy privet fruits, phellinus, cistanche, soroseris gillii, white peony roots and the like. Chinese medicinal materials are selected to prepare the medicine composition for treating infantile viral myocarditis, myocardial metabolism can be improved, heart muscles are nourished, heart cells are protected, the disease resistance of the heart muscles is improved, viruses can be directly killed, damage to the heart muscles caused by the viruses is relieved, anti-virus and integral regulation combined action effects are achieved, side effects of long-term application of western medicines on human bodies are relieved, the medicine composition is an ideal medicine for treating the myocarditis, contains a large number of active components and can be extensively applied to clinical practice, raw materials are cheap, and a preparation method is simple.
Description
The divisional application of the patent of " a kind of pharmaceutical composition for the treatment of infantile viral myocarditis " that the present invention is application number is 2014103933369, the applying date, to be August 12, denomination of invention in 2014 be.
Technical field
The present invention relates to pediatrics, relate in particular to a kind of pharmaceutical composition for the treatment of infantile viral myocarditis.
Background technology
Viral myocarditis (VM) in recent years sickness rate obviously increases, and constitutes serious threat to the health of child, and because its clinical manifestation is varied, state of an illness weight great disparity, auxiliary examination poor specificity, brings certain difficulty to clinical diagnosis and treatment.In recent years, due to the extensive use of antibiotic medicine, rheumatic myocarditis sickness rate is obvious must decline, but viral myocarditis sickness rate but increases.Research according to science finds, viral myocarditis morbidity can be caused by the direct invasion of virus, or poisoning intrusion health causes immune system to be damaged causing, and morbidity mostly is child or teenager, in addition spring is the season of virus breeding, and prevention myocarditis more should people together vigilant.Recent study finds, utilizes combination of Chinese and Western medicine method to treat viral myocarditis and is subject to gratifying effect.Therefore, Chinese medicine controls in symptom for viral myocarditis, the improvement of cardiac function, and the recovery of cardiac muscle and the adjustment aspect of whole body function obtain the accreditation of extensive patients, therefore needs constantly to find new effective medicine.
Summary of the invention
The object of this invention is to provide a kind of pharmaceutical composition for the treatment of infantile viral myocarditis.
In order to realize object of the present invention, the invention provides the purposes of compositions in the medicine of preparation treatment infantile viral myocarditis, described compositions comprises the crude drug of following weight portion: Ramulus Cinnamomi 10-20 part, Radix Glycyrrhizae 1-10 part, Pericarpium Citri Reticulatae 1-10 part, Radix Achyranthis Bidentatae 1-10 part and Fructus Ligustri Lucidi 1-10 part.
Preferably, described compositions comprises the crude drug of following weight portion: Ramulus Cinnamomi 12 parts, 8 parts, Radix Glycyrrhizae, Pericarpium Citri Reticulatae 6 parts, Radix Achyranthis Bidentatae 8 parts and Fructus Ligustri Lucidi 8 parts.
Preferably, described compositions also comprises the crude drug of following weight portion: Phellinus igniarius (L. ex Fr.) Quel. 1-10 part, Herba Cistanches 5-15 part, thin,tough silk hair chrysanthemum 5-20 part, Radix Paeoniae Alba 1-10 part, Desmodium podocarpum D C． 1-10 part, Rubus xanthocarpus 1-20 part, Radix Rhodiolae 1-5 part, Caulis et Folium Hyptidis suaveolentis 1-10 part, Folium Eriobotryae 1-10 part, close flowers and plants 10-20 part, Flos kerriae japonicae 1-10 part, Caulis Lonicerae 1-10 part, Herba Tricyrtis Pilosae 1-10 part, Flos Celosiae Cristatae 5-25 part, Salvia japonica Thunb. 10-20 part and Herba Fimbristylis dichotomae 1-10 part.
Preferably, described compositions also comprises the crude drug of following weight portion: Phellinus igniarius (L. ex Fr.) Quel. 8 parts, Herba Cistanches 6 parts, thin,tough silk hair chrysanthemum 6 parts, the Radix Paeoniae Alba 5 parts, Desmodium podocarpum D C． 9 parts, Rubus xanthocarpus 10 parts, Radix Rhodiolae 3 parts, Caulis et Folium Hyptidis suaveolentis 6 parts, Folium Eriobotryae 6 parts, close flowers and plants 15 parts, Flos kerriae japonicae 6 parts, Caulis Lonicerae 9 parts, Herba Tricyrtis Pilosae 9 parts, Flos Celosiae Cristatae 6 parts, Salvia japonica Thunb. 15 parts and Herba Fimbristylis dichotomae 6 parts.
Preferably, described medicine can be tablet, dispersible tablet, disintegrating tablet, rapidly dissolving tablet, enteric coatel tablets, collutory or decoction.
For compositions of the present invention, according to the prescription compatibility theory of " monarch, minister, help, make ", Rubus xanthocarpus and Desmodium podocarpum D C． are monarch drug; Phellinus igniarius (L. ex Fr.) Quel., Herba Cistanches, Ramulus Cinnamomi, thin,tough silk hair chrysanthemum, Radix Rhodiolae, Caulis et Folium Hyptidis suaveolentis, Folium Eriobotryae, close flowers and plants are ministerial drug; Pericarpium Citri Reticulatae, Radix Achyranthis Bidentatae, Fructus Ligustri Lucidi, the Radix Paeoniae Alba, Flos kerriae japonicae, Caulis Lonicerae, Herba Tricyrtis Pilosae, Flos Celosiae Cristatae, Salvia japonica Thunb., Herba Fimbristylis dichotomae are adjuvant drug; Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription, for making medicine.The efficient combination of said medicine, supports mutually, and the curative effect for the treatment of infantile viral myocarditis is obvious.
Detailed description of the invention
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Unless otherwise stated, the percent in the present invention is percetage by weight.
Embodiment decoction of the present invention
Take Ramulus Cinnamomi 12 grams, 8 grams, Radix Glycyrrhizae, Pericarpium Citri Reticulatae 6 grams, Radix Achyranthis Bidentatae 8 grams, Fructus Ligustri Lucidi 8 grams, Phellinus igniarius (L. ex Fr.) Quel. 8 grams, Herba Cistanches 6 grams, thin,tough silk hair chrysanthemum 6 grams, the Radix Paeoniae Alba 5 grams, Desmodium podocarpum D C． 9 grams, Rubus xanthocarpus 10 grams, Radix Rhodiolae 3 grams, Caulis et Folium Hyptidis suaveolentis 6 grams, Folium Eriobotryae 6 grams, close flowers and plants 15 grams, Flos kerriae japonicae 6 grams, Caulis Lonicerae 9 grams, Herba Tricyrtis Pilosae 9 grams, Flos Celosiae Cristatae 6 grams, Salvia japonica Thunb. 15 grams and Herba Fimbristylis dichotomae 6 grams; pulverize; add 3000 milliliters, water; heating 3 hours under the condition of backflow; filter; obtain filtrate and filtering residue; filtrate is cooled to room temperature, obtains decoction of the present invention.
Experimental example
Physical data
Be collected in year March in February, 2013 to 2014 to the medical 50 children of my institute, wherein man 25 example, women 25 example, age 5-12 year, average 7.1 years old; Course of disease 8-42d, average 25d.
Diagnosis and inclusive criteria
Diagnostic criteria is with reference to diagnosis of viral myocarditis standard (department of pediatrics branch of Chinese Medical Association cardioangiology papova dallas criteria [J] the Pediatrics magazine of the academic meeting of national heart disease in children in JIUYUE, 1999 Kunming meeting revision, 2000,38 (2): 2).
Inclusive criteria: 1) age 5-12 year, accept take Chinese medicine decoction; 2) clinical main suit is cardiopalmus, weak; 3) cardiac dilatation (x-ray, echocardiography have one of performance); 4) ECG change, mainly lead lasting more than the 4d of (I, II, aVF, V5) ST-T change with dynamic change based on 2 of R ripple or more than 2, antrum, atrioventricular block, the complete right side or left bundle branch block, Cheng Lianlv, many types of, paired or parallel premature beat, low-voltage (except neonate) and abnormality Q wave; 5) enzyme labeled compound assay creatine kinase isozyme (CK-MB) and hydroxybutyric dehydrogenase (HBDH) raise (detection of Beckman full automatic biochemical apparatus performance rate method); 6) etiological diagnosis foundation: be separated to virus in feces, throat swab or blood.
The decoction prepared in embodiment is used to treat, every day twice, oral 150 milliliters at every turn, treatment 10 days continuously.
Observation index
Measure Bardhan index before and after treatment (0-3 level represents that clinical symptoms is nothing, slight, moderate, severe respectively).
Efficacy assessment standard
Clinical cure: clinical symptoms, sign all disappear, electrocardiographic oscillogram is observed or continuous more than 2 times electrocardios recover normal, and myocardial enzymes (CK-MB, HBDH) recovers normal.Effective: cardiopalmus symptom disappears substantially, electrocardiographic oscillogram observation or electrocardiogram make moderate progress, and systolia ectopica number reduces >=50%, when continuing, between one, comparatively treatment is front shortens more than 50%, or take place frequently transfer to multiple or multiple transfer to accidental, myocardial enzymes (CK-MB, HBDH) reduce.Invalid: cardiopalmus symptom and electrocardio ripple or electrocardiogram unchanged or increase the weight of, myocardial enzymes is all without improvement.
Result
Before and after treatment, Bardhan index compares and sees the following form
Note: with organize treat before compare * P<0.05
Before and after treatment, CK-MB and HBDH level compares and sees the following form
Note: with organize treat before compare * P<0.05
Through treatment, find in 50 routine patients, clinical cure 45 example, effective 4 examples, invalid 1 example.
Claims (5)
1. the purposes of compositions in the medicine of preparation treatment infantile viral myocarditis, it is characterized in that, described compositions comprises the crude drug of following weight portion: Ramulus Cinnamomi 10-20 part, Radix Glycyrrhizae 1-10 part, Pericarpium Citri Reticulatae 1-10 part, Radix Achyranthis Bidentatae 1-10 part and Fructus Ligustri Lucidi 1-10 part.
2. purposes according to claim 1, is characterized in that, described compositions comprises the crude drug of following weight portion: Ramulus Cinnamomi 12 parts, 8 parts, Radix Glycyrrhizae, Pericarpium Citri Reticulatae 6 parts, Radix Achyranthis Bidentatae 8 parts and Fructus Ligustri Lucidi 8 parts.
3. purposes according to claim 1 and 2; it is characterized in that, described compositions also comprises the crude drug of following weight portion: Phellinus igniarius (L. ex Fr.) Quel. 1-10 part, Herba Cistanches 5-15 part, thin,tough silk hair chrysanthemum 5-20 part, Radix Paeoniae Alba 1-10 part, Desmodium podocarpum D C． 1-10 part, Rubus xanthocarpus 1-20 part, Radix Rhodiolae 1-5 part, Caulis et Folium Hyptidis suaveolentis 1-10 part, Folium Eriobotryae 1-10 part, close flowers and plants 10-20 part, Flos kerriae japonicae 1-10 part, Caulis Lonicerae 1-10 part, Herba Tricyrtis Pilosae 1-10 part, Flos Celosiae Cristatae 5-25 part, Salvia japonica Thunb. 10-20 part and Herba Fimbristylis dichotomae 1-10 part.
4. purposes according to claim 3; it is characterized in that, described compositions also comprises the crude drug of following weight portion: Phellinus igniarius (L. ex Fr.) Quel. 8 parts, Herba Cistanches 6 parts, thin,tough silk hair chrysanthemum 6 parts, the Radix Paeoniae Alba 5 parts, Desmodium podocarpum D C． 9 parts, Rubus xanthocarpus 10 parts, Radix Rhodiolae 3 parts, Caulis et Folium Hyptidis suaveolentis 6 parts, Folium Eriobotryae 6 parts, close flowers and plants 15 parts, Flos kerriae japonicae 6 parts, Caulis Lonicerae 9 parts, Herba Tricyrtis Pilosae 9 parts, Flos Celosiae Cristatae 6 parts, Salvia japonica Thunb. 15 parts and Herba Fimbristylis dichotomae 6 parts.
5. purposes according to claim 4, is characterized in that, described medicine can be tablet, dispersible tablet, disintegrating tablet, rapidly dissolving tablet, enteric coatel tablets, collutory or decoction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410834156.XA CN104435262B (en) | 2014-08-12 | 2014-08-12 | A kind of pharmaceutical composition for the treatment of infantile viral myocarditis |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410834156.XA CN104435262B (en) | 2014-08-12 | 2014-08-12 | A kind of pharmaceutical composition for the treatment of infantile viral myocarditis |
| CN201410393336.9A CN104127548B (en) | 2014-08-12 | 2014-08-12 | Pharmaceutical composition for treating viral myocarditis in children |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410393336.9A Division CN104127548B (en) | 2014-08-12 | 2014-08-12 | Pharmaceutical composition for treating viral myocarditis in children |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104435262A true CN104435262A (en) | 2015-03-25 |
| CN104435262B CN104435262B (en) | 2015-08-26 |
Family
ID=51800570
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410834156.XA Expired - Fee Related CN104435262B (en) | 2014-08-12 | 2014-08-12 | A kind of pharmaceutical composition for the treatment of infantile viral myocarditis |
| CN201410393336.9A Expired - Fee Related CN104127548B (en) | 2014-08-12 | 2014-08-12 | Pharmaceutical composition for treating viral myocarditis in children |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410393336.9A Expired - Fee Related CN104127548B (en) | 2014-08-12 | 2014-08-12 | Pharmaceutical composition for treating viral myocarditis in children |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN104435262B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102772748A (en) * | 2012-08-21 | 2012-11-14 | 杨高林 | Traditional Chinese medicine preparation for treating liver-depression qi-stagnation type viral myocarditis and preparation method thereof |
| CN103120791A (en) * | 2013-03-25 | 2013-05-29 | 华梅 | Traditional Chinese medicine composition for treating vital myocarditis and preparation method thereof |
| CN103230457A (en) * | 2013-05-09 | 2013-08-07 | 徐金星 | Traditional Chinese medicine composition for treating viral myocarditis and preparation method and use thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1123357C (en) * | 1999-06-25 | 2003-10-08 | 刘永香 | Powdered medicine for conditioning viscera and whole body |
-
2014
- 2014-08-12 CN CN201410834156.XA patent/CN104435262B/en not_active Expired - Fee Related
- 2014-08-12 CN CN201410393336.9A patent/CN104127548B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102772748A (en) * | 2012-08-21 | 2012-11-14 | 杨高林 | Traditional Chinese medicine preparation for treating liver-depression qi-stagnation type viral myocarditis and preparation method thereof |
| CN103120791A (en) * | 2013-03-25 | 2013-05-29 | 华梅 | Traditional Chinese medicine composition for treating vital myocarditis and preparation method thereof |
| CN103230457A (en) * | 2013-05-09 | 2013-08-07 | 徐金星 | Traditional Chinese medicine composition for treating viral myocarditis and preparation method and use thereof |
Non-Patent Citations (2)
| Title |
|---|
| 赵兵: "心肌消炎丸治疗心肌炎2例的初步体会", 《心功能杂志》 * |
| 黄忠新: "病毒性心肌炎辨治八法", 《河北中医》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104127548B (en) | 2015-04-01 |
| CN104435262B (en) | 2015-08-26 |
| CN104127548A (en) | 2014-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104225403B (en) | One kind treats phthisical pharmaceutical composition and preparation method and purposes | |
| CN104127548B (en) | Pharmaceutical composition for treating viral myocarditis in children | |
| CN103933280A (en) | Traditional Chinese medicine composition for treating PCI (percutanecus coronary intervention) postoperative angina of phlegm-obstructing heart vessel type coronary heart disease and application thereof | |
| CN103893601B (en) | A kind of medicament for the treatment of mumps | |
| CN103550477B (en) | Medicament for treating herpes zoster | |
| CN105362797A (en) | Traditional Chinese medicine for treating myocarditis | |
| CN109528798A (en) | Purposes of the newborn lettuce alcohol extract in treatment psoriasis | |
| CN104706813A (en) | Mulberry-glossy privet fruit health composition | |
| CN105194352B (en) | A kind of Chinese medicine composition and preparation method thereof improving learning and memory | |
| CN104687032A (en) | Health caring echinacea health product | |
| CN104740079A (en) | Phyllanthus emblica health-care traditional Chinese medicine composition | |
| CN104705634A (en) | Lucid ganoderma healthcare product for protecting health | |
| CN103142986B (en) | Medicine for treating arrhythmia | |
| CN104771560B (en) | A kind of medicine for the treatment of mania | |
| CN104225435A (en) | Traditional Chinese medicine preparation for treating turbid phlegm obstructing type coronary heart disease | |
| CN105288325A (en) | Traditional Chinese medicine for treating arrhythmia caused by deficiency of both vital energy and yin | |
| CN103169937B (en) | Drug for treating arrhythmia | |
| CN104825809A (en) | Medicament for treating peripheral facial paralysis | |
| CN104906438A (en) | Medicine for treating acute myocarditis | |
| CN104172174A (en) | Preparation for preventing heatstroke in electric outdoor working | |
| CN104706815A (en) | Wolfberry-pseudo-ginseng health composition | |
| CN103893600A (en) | Traditional Chinese medicinal composition for treating scapulohumeral periarthritis | |
| CN103446410A (en) | Traditional Chinese medicine preparation for treating viral myocarditis | |
| CN102631489B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN102727605A (en) | Oral liquid for treating vital myocarditis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: THE FIRST HOSPITAL OF YULIN Free format text: FORMER OWNER: HAO HONGJUAN Effective date: 20150724 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Gao Fanhua Inventor after: Feng Juan Inventor after: Wang Yingjuan Inventor after: Han Yongjun Inventor after: Han Jianlun Inventor after: Shi Gaifang Inventor after: Zhang Jie Inventor after: Cui Wei Inventor after: Yang Yong Inventor after: Wang Hui Inventor before: Hao Hongjuan |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: HAO HONGJUAN TO: GAO FANHUA WANG YINGJUAN HAN YONGJUN HAN JIANLUN SHI GAIFANG ZHANG JIE CUI WEI YANG YONG WANG HUI FENG JUAN |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150724 Address after: 719000, 93, Yu Xi Road, Yulin hi tech Zone, Shaanxi Applicant after: Yulin City First Hospital Address before: 272000 Jining Jining high tech Zone, Lunan Road, Shandong, Shandong Province Social Welfare Center Applicant before: Hao Hongjuan |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150826 Termination date: 20160812 |